Metagenomi, Inc., a gene editing biotechnology company, develops therapeutics for patients using metagenomics-derived genome editing toolbox in the United States. The company is headquartered in Emeryville, California.
| Revenue (TTM) | $22.33M |
| Gross Profit (TTM) | $-71.69M |
| EBITDA | $-87.55M |
| Operating Margin | -1970.00% |
| Return on Equity | -49.00% |
| Return on Assets | -23.40% |
| Revenue/Share (TTM) | $0.60 |
| Book Value | $3.66 |
| Price-to-Book | 0.34 |
| Price-to-Sales (TTM) | 2.23 |
| EV/Revenue | 0.712 |
| EV/EBITDA | — |
| Quarterly Earnings Growth (YoY) | 0.00% |
| Quarterly Revenue Growth (YoY) | -69.80% |
| Shares Outstanding | $37.65M |
| Float | $25.44M |
| % Insiders | 18.96% |
| % Institutions | 19.32% |
Volatility is currently expanding
Shareholders are urged to contact the firm immediately at no cost or obligation, as there may be limited time to enforce your rights. We would handle the matter on a contingent fee basis, whereby you would not be responsible for out-of-pocket payment of our legal fees or expenses.
EMERYVILLE, Calif., May 28, 2026 (GLOBE NEWSWIRE) -- Metagenomi Therapeutics, Inc. (Nasdaq: MGX) (the “Company”), an in vivo genome editing company capitalizing on its proprietary technologies to create curative genetic medicines for patients, today announced that Jian Irish, Ph.D.
Metagenomi Therapeutics (MGX) came out with a quarterly loss of $0.61 per share versus the Zacks Consensus Estimate of a loss of $0.6. This compares to a loss of $0.68 per share a year ago.
On track for regulatory submission of MGX-001 to advance global clinical program, including investigational new drug application (“IND”) in 4Q 2026 Publication in Nature Structural & Molecular Biology highlights potential of MG119-28, a proprietary compact CRISPR nuclease with enhanced genome editing efficiency $140.2 million in cash, cash equivalents, and available-for-sale marketable securities as of March 31, 2026, with runway anticipated to support operations through 4Q 2027 EMERYVILLE, Calif., May 11, 2026 (GLOBE NEWSWIRE) -- Metagenomi Therapeutics, Inc. (Nasdaq: MGX) (the “Company”), an in vivo genome editing company capitalizing on its proprietary technologies to create curative genetic medicines for patients, today reported financial results for the first quarter ended March 31, 2026, and provided business updates.
Metagenomi Announces Publication in Nature Structural & Molecular Biology Highlighting Proprietary Compact CRISPR Nuclease with Enhanced Editing Efficiency
Shareholders are urged to contact the firm immediately at no cost or obligation, as there may be limited time to enforce your rights. We would handle the matter on a contingent fee basis, whereby you would not be responsible for out-of-pocket payment of our legal fees or expenses.
